The FDA approved a supplement to biologics licence application 761498 on 2 September 2026, covering AVTOZMA — tocilizumab-anoh, from Celltrion. This is a change to an existing licence for an approved tocilizumab biosimilar, not a new molecule and not a new indication.
What a supplement covers can range from a manufacturing change to a new presentation or a labelling revision, and the application record does not by itself say which. Treat it as an administrative development in the tocilizumab biosimilar supply until the specific change is published.
The practical significance for most prescribers is competitive rather than clinical. More licensed tocilizumab products means more procurement options for rheumatoid arthritis, giant cell arteritis and cytokine release syndrome, which in India matters mainly through price — biosimilar tocilizumab has been available here for some time and the FDA's decisions do not govern CDSCO's.
- No prescribing change follows from this; the biosimilar was already licensed.
- Check which presentation your pharmacy stocks if you are switching between tocilizumab products.
- Record the specific brand and batch when prescribing any biosimilar biologic.
- FDA approval does not imply CDSCO approval, and Indian availability follows its own track.
- Wait for the published labelling before assuming an indication has changed.
Why it matters
Supply and price of tocilizumab biosimilars move with these approvals even when the clinical picture does not.
Don't overread it
A licence supplement is an administrative action, not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free